SlideShare une entreprise Scribd logo
1  sur  48
The Difference Between Practice and Research – What the FDA Expects You to Understand Harvey M. Arbit, PharmD, MBA, RAC, CCRP University of Minnesota Director, IND/IDE Assistance Program,  Academic Health Center Adjunct Associate Professor, College of Pharmacy Phone 612-625-0930 Fax 612-625-3956 E-mail  [email_address] www.ahc.umn.edu/research/ind-ide/
Outline ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Practice vs Research
Clinical Practice ≠ Clinical Research ,[object Object],[object Object],[object Object]
Clinical Investigation (Drug Research) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Trials vs Medical Practice ,[object Object],[object Object],[object Object]
Practice of Medicine ,[object Object]
"Off-Label" Use of Marketed Drugs, Biologics and Medical Devices ,[object Object],[object Object],[object Object],[object Object],[object Object]
Clinical Trial ,[object Object],[object Object],[object Object]
Investigational Use of Marketed Drugs, Biologics and Medical Devices   ,[object Object],[object Object],[object Object]
Investigational Use of Marketed Drugs, Biologics and Medical Devices (cont.) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
IND Assessment Process ,[object Object],[object Object],[object Object],[object Object],[object Object]
 
Oncology Drugs ,[object Object],[object Object],[object Object]
Sponsor and Investigator
http://aapp.org/pdf/HansMayoPresentation.pdf
Sponsor 21 CFR 312.3(b) ,[object Object],[object Object]
Sponsor-Investigator   21 CFR 312.3(b) ,[object Object],[object Object],[object Object]
Form FDA 1571 ,[object Object]
When a sponsor signs the 1571  he/she agrees to the following: ,[object Object],[object Object],[object Object],[object Object],[object Object]
Responsibilities of  Sponsors  and Investigators   21 CFR 312 Subpart D ,[object Object],[object Object]
Investigator   21 CFR 312.3(b) ,[object Object]
Form FDA 1572 ,[object Object]
When an investigator signs the 1572 he/she commits to the following: ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
1572 (Cont.) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Responsibilities of  Sponsors and  Investigators   21 CFR 312 Subpart D ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Good Clinical Practice (GCP)
 
 
Protocol elements for IND   21 CFR 312.23(a)(6)(iii) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Elements of a Clinical Trial Protocol   (GCP section 6) ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Protocol Compliance It doesn’t matter who wrote the protocol – or whether the trial is funded by the DHHS or regulated by FDA –  NO change can be implemented without prior IRB approval  (except to mitigate immediate hazard).  The plan submitted to (and approved by) the IRB cannot be changed without approval. Some changes must also be submitted to the FDA.
Clinical Trial Monitoring
 
Proper Monitoring (FDA Guideline for the Monitoring of Clinical Investigations) ,[object Object],[object Object],[object Object],[object Object]
Purpose of Monitoring   (GCP section 5.18.1) ,[object Object],[object Object],[object Object],[object Object],[object Object]
Site/Clinical Monitoring ,[object Object],[object Object],[object Object]
Focus of Monitoring Visits ,[object Object],[object Object],[object Object],[object Object],[object Object]
Data & Safety Monitoring Board (DSMB)
DSMB ,[object Object],[object Object],[object Object]
DSMB Composition ,[object Object],[object Object],[object Object],[object Object]
Data Safety Monitoring  GCP 5.5.2 ,[object Object],[object Object]
What FDA Looks For
What FDA Looks For ,[object Object],[object Object],[object Object],[object Object],[object Object]
What FDA Looks For (cont.) ,[object Object],[object Object],[object Object]
Regulatory Actions ,[object Object],[object Object],[object Object],[object Object],[object Object]
Summary –  Points of Importance ,[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Are there any Questions ? Thank you !

Contenu connexe

Tendances

KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIKKEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
Dr. Suchismita Banik
 
responsibility of an investigator
responsibility of an investigatorresponsibility of an investigator
responsibility of an investigator
drodo2002
 
Project management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 mayProject management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 may
Sanjay Akhani
 

Tendances (20)

KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIKKEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
KEY STAKEHOLDERS IN CLINICAL RESEARCH SUCHISMITA BANIK
 
Sponsor Responsibilities ppt
Sponsor  Responsibilities pptSponsor  Responsibilities ppt
Sponsor Responsibilities ppt
 
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLSReconciliation and Literature Review and Signal Detection_Katalyst HLS
Reconciliation and Literature Review and Signal Detection_Katalyst HLS
 
Essential Regulatory Documents in Clinical Trials
Essential Regulatory Documents in Clinical TrialsEssential Regulatory Documents in Clinical Trials
Essential Regulatory Documents in Clinical Trials
 
standard operating procedure
standard operating procedurestandard operating procedure
standard operating procedure
 
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
Roles and Responsibilities of sponsor in conducting clinical trials as per GC...
 
Informed consent
Informed consentInformed consent
Informed consent
 
Investigator Role and Responsibilities
Investigator Role and ResponsibilitiesInvestigator Role and Responsibilities
Investigator Role and Responsibilities
 
Clinical trail team ( stake holders )
Clinical trail team ( stake holders )Clinical trail team ( stake holders )
Clinical trail team ( stake holders )
 
Inform consents form
Inform consents form Inform consents form
Inform consents form
 
Informed consent in Clinical Trials
Informed consent in Clinical TrialsInformed consent in Clinical Trials
Informed consent in Clinical Trials
 
Icmr guideline
Icmr guidelineIcmr guideline
Icmr guideline
 
Code of ethics in clinical trial
Code of ethics in clinical trialCode of ethics in clinical trial
Code of ethics in clinical trial
 
responsibility of an investigator
responsibility of an investigatorresponsibility of an investigator
responsibility of an investigator
 
Turacoz - Clinical Study Report
Turacoz - Clinical Study ReportTuracoz - Clinical Study Report
Turacoz - Clinical Study Report
 
Best practices for maintaining and storing essential documents in clinical re...
Best practices for maintaining and storing essential documents in clinical re...Best practices for maintaining and storing essential documents in clinical re...
Best practices for maintaining and storing essential documents in clinical re...
 
Role of medical writers
Role of medical writersRole of medical writers
Role of medical writers
 
SAE resporting for case 005
SAE resporting for case 005SAE resporting for case 005
SAE resporting for case 005
 
Project management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 mayProject management in clinical research sanjay akhani 8 may
Project management in clinical research sanjay akhani 8 may
 
Qa and Qc in clinical research sem ll (1)
Qa and Qc in clinical research sem ll (1)Qa and Qc in clinical research sem ll (1)
Qa and Qc in clinical research sem ll (1)
 

Similaire à The difference between practice and research 111607

Guidance for industry for IND application
Guidance for industry for IND applicationGuidance for industry for IND application
Guidance for industry for IND application
Bharat Kumar
 
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
ClinosolIndia
 

Similaire à The difference between practice and research 111607 (20)

Investigational new drug application
Investigational new drug application Investigational new drug application
Investigational new drug application
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdfINVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
INVESTIGATIONAL NEW DRUG [IND] APPLICATION SUBMISSION (1).pdf
 
Guidance for industry for IND application
Guidance for industry for IND applicationGuidance for industry for IND application
Guidance for industry for IND application
 
The Rough Waters of the Regulatory Environment
The Rough Waters of the Regulatory EnvironmentThe Rough Waters of the Regulatory Environment
The Rough Waters of the Regulatory Environment
 
IND APPLICATION
IND APPLICATIONIND APPLICATION
IND APPLICATION
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
FDA 2013 Clinical Investigator Training Course: Investigator Responsibilities...
FDA 2013 Clinical Investigator Training Course: Investigator Responsibilities...FDA 2013 Clinical Investigator Training Course: Investigator Responsibilities...
FDA 2013 Clinical Investigator Training Course: Investigator Responsibilities...
 
IND(Investigational New Drug Application).pptx
IND(Investigational New Drug Application).pptxIND(Investigational New Drug Application).pptx
IND(Investigational New Drug Application).pptx
 
Investigational New Drug Application
Investigational New Drug ApplicationInvestigational New Drug Application
Investigational New Drug Application
 
IND Application Process and Best Practices
IND Application Process and Best PracticesIND Application Process and Best Practices
IND Application Process and Best Practices
 
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
Regulatory Compliance in Clinical Research: Navigating the FDA and Other Agen...
 
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptxPART 1 _ Documentation of drug trials and regulatory filings (1).pptx
PART 1 _ Documentation of drug trials and regulatory filings (1).pptx
 
Ind by pankaj
Ind by pankajInd by pankaj
Ind by pankaj
 
Ind 30
Ind 30Ind 30
Ind 30
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
INVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATIONINVESTIGATIONAL NEW DRUG APPLICATION
INVESTIGATIONAL NEW DRUG APPLICATION
 
IND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspectiveIND (Investigational New Drug) industrial perspective
IND (Investigational New Drug) industrial perspective
 
Cfr 21 part 312
Cfr 21 part 312 Cfr 21 part 312
Cfr 21 part 312
 
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
BP804 ET: PHARMACEUTICAL REGULATORY SCIENCE (Theory)2. unit ii, chapter-1 reg...
 

Plus de Lanka Praneeth

Plus de Lanka Praneeth (10)

Peg copeg dr_letter_01_08
Peg copeg dr_letter_01_08Peg copeg dr_letter_01_08
Peg copeg dr_letter_01_08
 
Naidoo
NaidooNaidoo
Naidoo
 
Kpo solutions
Kpo solutionsKpo solutions
Kpo solutions
 
How to make_your_first_robot
How to make_your_first_robotHow to make_your_first_robot
How to make_your_first_robot
 
Guidance on 1572
Guidance on 1572Guidance on 1572
Guidance on 1572
 
Essential documents and_managing_trial_files
Essential documents and_managing_trial_filesEssential documents and_managing_trial_files
Essential documents and_managing_trial_files
 
Electronic trial master filest
Electronic trial master filestElectronic trial master filest
Electronic trial master filest
 
Dispersion stati
Dispersion statiDispersion stati
Dispersion stati
 
Clifford wilke
Clifford wilkeClifford wilke
Clifford wilke
 
Poster
PosterPoster
Poster
 

Dernier

Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
PECB
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
Chris Hunter
 

Dernier (20)

Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Measures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and ModeMeasures of Central Tendency: Mean, Median and Mode
Measures of Central Tendency: Mean, Median and Mode
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
ICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptxICT Role in 21st Century Education & its Challenges.pptx
ICT Role in 21st Century Education & its Challenges.pptx
 
Measures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SDMeasures of Dispersion and Variability: Range, QD, AD and SD
Measures of Dispersion and Variability: Range, QD, AD and SD
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Beyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global ImpactBeyond the EU: DORA and NIS 2 Directive's Global Impact
Beyond the EU: DORA and NIS 2 Directive's Global Impact
 
Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1Código Creativo y Arte de Software | Unidad 1
Código Creativo y Arte de Software | Unidad 1
 
Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
Paris 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activityParis 2024 Olympic Geographies - an activity
Paris 2024 Olympic Geographies - an activity
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 

The difference between practice and research 111607